BiomX (PHGE) 30 Mar 222021 Q4 Earnings call transcript

Greetings, welcome to BiomX Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode, and question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to Marina Wolfson, Senior Vice President of Finance. Ms. begin. now may you Wolfson,

Time Thank this you XXXX The fourth-quarter full-year the of biomx.com. AM the release on Section be our Investors website will welcome results and be to at Eastern X:XX financial after call. replay available BiomX and corporate can became found of and A just and website. today call update news on our conference available

that like I'd statements. statements to review not Harbor statements Safe historic All call forward-looking begin, the on provision. may this we are deemed or factual Before be

potential which law, instance, to we cash opportunities conference cash except product actual equivalents, For value, in potential of if we're timing, results on growth press additional results could candidates using deposits. shareholder aim, and of short-term cause the design, statements. forward-looking earlier, and to pre including update when do forward-looking and market sufficiency potential discuss clinical potential our existing and receipt the of in benefits final we Harbor statements milestones of is our risks call cash, The expected full that release, from The are forward-looking and outlined our noted website. met, statements provision, in interim today's these Safe the by is are not differ for our -clinical required as undertake trials,

Executive over With Officer Joining me to BiomX. Chief on the the of Solomon, morning call I Jonathan Jonathan. will this that, is turn call

everyone. you, Thank and good morning, Marina,

company. within dermatitis to we our With and now period could us by to with also and our months believe until is the significant entering most proof-of-concept at value Foundation investments the recent the company's generate end programs, the that on atopic cash Cystic in XX equity have year expected our in fibrosis I both take of seven begin the existing poised me next cystic history. are readouts the saying are well-positioned data on of expected financially Maruho impact time XXXX. At same Let exciting BiomX Fibrosis with the that we least

to existing loan our under Additional agreement tranches cash million may extend into runway mid-XXXX. of up further our $XX

controlled, patients. of need life-threatening surface CF it lung patients CF in p. XX,XXX resistant due and the infection of characterized patients by P. courses that following to Studies the this versus without bacteria And X infection Part which evaluate expression and significant a therefore the will XX are resistance. XX% strains suffer U.S. pulmonary to it. BXXXX, infected in and forming leads open leading antibiotic in to provide microbiological of the will activity cystic P. to found has COVID patients. a higher penetrate the surface randomized trial preclinical bacterium. chronically of shown and this and by infection address multi-drug substance starting Pharmacokinetic [Indiscernible] from most believe P. in A Biofilm this those than biofilm. approximately XX% the patients continued patients two impairing efficacy causes by no receive P. BXXXX recent in update each aeruginosa patients CF in is and aeruginosa, in trial associated CF that this showed program about me also estimated ratio. that eventually aeruginosa more unmet our is not one patients. these bacteria our XX, of for exacerbation's, common evaluate the this medical eight-year most chronic cohort of Biofilm dose infections can is in of potential Aeruginosa X.X longer opportunity prolonged, Part the to where its spectrum was of to of eight Research airway of bacterial a BXXXX Aeruginosa fibrosis. multiple P. studies, P. and and Aeruginosa Factor start in respiratory infection on genes leads lung point We we're the MDR. now metric P. The by by challenging chronic mortality with antibiotic safety wave. steeper enrollment the further candidate higher seeing progressively within contributor also XX% an chronic Aeruginosa, and of times epithelial CF of and Pseudomonas the with of being of CF CF that P. in mortality one and slower or developed BXXXX colonized also novel with develops dose the brief to cells repeated but to strains, the single ability is intracellular the in resistant morbidity chronically broad design. assemblage in safety to for to and a CF. aeruginosa childhood, phage of the have will patients placebo resistant into higher antibiotic death appearance admissions, infection antibiotic treatment BXXXX to plugging, function. remains Let pulling but estimated and patients. against be treatment show significant. really ascending be X to patients With conditions in of of BXXXX hospital clinical colonization due infection a decline. Chronic medical damage itself. In of a and shown and antibiotic one main caused for is the XX,XXX patients detrimental and only pulmonary infections results number age CF aeruginosa risk enclosing Aeruginosa enhancers worldwide, -free microbial address function demonstrated activity holds is be

receive in the ongoing in Fibrosis dosing XXXX from Part of January, quarter therapeutic the the study, now the the our equity investment. Part first Foundation study third in made The stock. And expect second its patient the $X initial we of Cystic of would conservative, and development BiomX be a award Phase foundation quarter to Upon the readout readout have for of of proud December, XXXX. an X million. is to the have to we support In of study. development X million the as Xb/Xa from of common tranche support BiomX completion right award structured BXXXX. of announced X foundation We're from also in So of in the Part investment on in $X

dermatitis me atopic Now, to program. the turn let

represents atopic We phage baseline leading aureus, which By need, remains not candidate Atopic horse bacterium the developing topical at improvement. a the therapeutic BXXXX $X market the of believe targeting as triple significant associated exacerbation the only a with are we burden, Staphylococcus its BXXXX state, staff inflammation the the aureus, to the in product or clinical but years. and is next skin commercial expected potential opportunity to has billion, shift reducing dermatitis. development valued dermatitis to over to Staph composition microbiome unmet attractive, with current few

quarter, to the opportunity, we with developing for agreement maximize market we Last BXXXX. Maruho the recognize this announced relationships of program. Given the strategic an importance value of size the

program. planned largest price. market in Maruho's our an to to in pleased came other expertise is the as full-year programs, BXXXX expected in we to clinic cancer over our and share X, a Maruho colorectal our Operations, Phase cover this stock the initial Vice our are have our of therapeutic I'd Finance With XXXX. the common form and very Maruho to financial the support like we enter -clinical area to As call the support results program well. for primarily surrounding and pre BiomX. fourth-quarter the also efforts candidate President focus respect to dermatology next the expect anticipate million year, fourth-quarter exceptional of results. the for premium Wolfson, our in CF now to candidate company to IBD their Senior turn the study. of $X build our financial in We Similar for investment to purchased brings Marina Japan, XXXX intended and the data product this equity in product Funding out at investment is our support X of to from Foundation,

Thank you, Jonathan.

earlier reminder, the a As and also Form later the issued today. more you press today, information highlights. in XX-K, detail financial in our we I walk release our through is be brief available in filed some of will will which

to such company, in number directors operational our million and to conducting expenses XXXX, to -clinical and Development to for mainly prior and related operating with an XX, research The related officers expenses, related increase of compensation, expenses stock-based salaries as by an facility. product salaries mainly The to fees cash from increase investor clinical partially our million for due balance deposits current for in due in resulting insurance, the clinical an estimate the deposits be activities cash for $XX.X from due in due to $XX.X in financing candidates of to prior $XX.X in December year. XXst, period higher event fund cash expenses to due for operating expenses $X.X Israeli and pre and increase was were was offset in million an activities. $XX.X operating was by $XX.X $XX.X XXXX, used cash equivalents growth As and XXXX and moving and XXst, XXXX. as The were and prior primarily compared of employees of increase year. year XXXX. into million primarily activities provided relations compared to met and used cash, XXXX Research to was net a and loss the in December net primarily public the short-term increased XXXX. million and same increase activities, levels associated new of XXXX development million growth expenses to trials listing employees as to expenses Innovation the million the offset end $XX.X related due to year. also by the of due activity to Net compared in will company's operating and that through million and and increase short-term the General million in compared $XX.X the sufficient number Net administrative in grants the were the the existing compared ended of million Authority. cash for and December $XX.X plan increase We was

debt Additional for remarks. specified tranches Jonathan. under the And available facility extend further to company runway I'll closing turn that back venture of certain first XXXX. cash company's the Jonathan to satisfaction of half the over call upon now, become can the his its would for milestones

Marina. you, Thank

well-positioned atopic exceptionally and dermatitis. the are in we we the the alike. programs proved be expected us call difficult biotechnology strong excited these opportunities market very there our this within sheet a prevailing same for months. readouts Operator. to for companies with We leading in time a value. of It's At grow for the obviously our fibrosis challenges that and both ahead either we these significant year conditions balance been programs lie are We'd candidates. lead product or recognize XX the next ongoing investors clinical and now have shareholder about opportunity that also like for open Despite the proof-of-concept will sector to questions. cystic successful, believe to

a question-and-answer We'll instructions]. you. be Thank [Operator conducting you. now Thank session.

Please comes with H.C. Our Pantginis Joe Wainwright. question. the first from line proceed of with your question

Jonathan. for taking you morning. question. the Hey, questions, Thank Two everyone, good

the on microbiological of then with data I and framework way, little a to what kind wanted X. in from patients? for XX data do this consider the it type I'll regard of of you bit get Part fourth program, expect, we a efficacy, quarter First, would the of ask success what a to CF

l two It's Good parts morning, the study. excellent Joe. we an think question. in have

the X, on a point. think of Part MAD significant placebo, which more treatments. in inflection EEG which focused study. six bit two those patients and X, readout Part on has You A are is is a actually third quarter SAD, on I are

high the low giving then and of few we're high So a dose. dose, dose, doses

we count. bacterial makes on not know relatively think that think we reduction surprises are we any that infections. expecting CF, So these succumbing might safety, in is a that signs some indication I know patients it's phage see is I exciting what actually that mostly we're there chance to microbiology just safe so of terms I the bacterial in again, And the of think is efficacy there,

some following So bacteria yielded of in have their you're point, the basically, clinical And significantly, I'm your to the that in design patients randomized two a studies. if you effect. the X the reduce one, that's to compassionate Part XX readout to going use

treatment. these we're count we're effect, to and to and to I such also some before as significant that after that for bacterial translate of greater order hopefully see X. days, magnitude, helps FEP measure the So a parameters want clinical patients on than to going should clarifying. treat We XX hope going signals

the with penetration dermatitis have morphology gives acne on gland the have different you the ask It skin program or dermatitis don't into certainly follicles aspects wanted I you does. feel underlying issues historically. Uh, issue, and what my issue? that a based skin sebaceous also been have you, an we'll pathology program little not the, and might And the we it would next call look I that of question and atopic were hair of to you there the I necessarily the and atopic guess at regarding reasons what different confidence look why when know,

length all through I It's industry colleagues. experts question. a We've great with think debated and the multiple with

I as acne, think in follicle. the said, resides the that you main the difference hair mature, inside

So swab, we're on with when inside superficially follicle. going we're not measuring seeing hair skin really the what's

recall, and going obviously faces material punch but count, you that's X, exactly to Phase a cosmetic volunteers. skin with not our of swab, a seen if the we biopsies, point in reduction we've measured study, So a biopsies the of actually the we're to do in

structure. was Penetration did a of that not clinical likely relatively just fact. It have the the and is phase a that think effect layers the most we to probably did deeper I happening the definitely we translate not So issue. saw case superficially. And large

lesions into the worse dermatitis. is we're bacteria, our staff before end, skin. on of the more more takeaways before there's atopic of from at there's levels right? staff. superficial lesions sort us implementing the bacteria gives at on and of look a It's Now, looking the and comfort high is and what When study in implant But staph you the are the the level themselves, low lesion you that when look at

level the then with swabs stream can the person, You different we at lesion see bacteria down. that different very same when in the go over of the you the lesions. lesions it's same away, skin see level high very, Interestingly, when looked goes

in it's unique So it no the acne. into that humans, acne looks above bacteria, only bacteria than more a and There's models. like no line an and only animal deep can C good is C infection, skin, the the most not right? other go of is one appears has shoulder there

probably I give study. of So we and think it's target. more aspect why in this unique success accessible that that's higher likelihood staph, again, is in a a And

That's very just me, can a just if housekeeping if helpful. could I Thank Marina. you. question indulge you And of ask

Sure.

fully the out, give Since be you today the would is count? diluted shares not as outstanding to XX-K just in the able of

your question. you for Thank Hi.

So today. first of later XX-K is all, to be the going filed

fully diluted. So we have approximately outstanding approximately $XX $XX million and million shares

Thank much, you very guys.

Thank you.

you. Thank

you. the Thank you. As [Operator a I'll Thank a moment reminder, assemble to Instruction] pause queue.

questions. Chardan. with Nakae Keay from Please comes question proceed next Our with your

Thank you.

of XXX X. else holding is for what start Jonathan, up the possibly Part CF, So

and Kay. Good morning, Good question

we've the is you studies, many there's terms CRO. delayed initiate your the what at think it now, issues because of as the positions manning of first these that of CROs non just like been COVID unlike has when companies with I in other seen

as be of seen both why So in a in so on guidance in more of site well decided atopic that's seen we've studies. we've as slower, we've that bit I the think give logistics both more that been lot our these And have time to CF. conservative,

do physicians opened that show while They we what's up now, patients. more And vulnerable waves enroll kind time. to a are that these we CF, sites make know for and time, to They're haven't they all the fits status on in in we these through patients got been them. talked -- with much the into not parameters when the worried, see there a their contact, clinics. and up is we and as lot sure of don't greater their to COVID. haven't we've with they know Specifically um, more the They

slightly seeing we're So slower. enrollment

that the which with around the additional up there's given think their vulnerability. been because specifically clinic, Issues in these a of companies showing So has experiencing manpower CF, [Indiscernible] it's issues. of difficulty lot and other they're so worried to I'd say are two about I uh, kind

matters of aeruginosa or finding testing fact sufficient simply the and for level And part shouldn't of with it the is that there it in of terms don't that it is just them but they think -- baseline that or infection have some is Pseudomonas of is is study. patients for presence screening chronic to of a it difficult the that, infection, be difficult -- to we that is, sort

think in bacteria they and So they important it's takeaway, I general have sufficient therapy amounts sort bacteria. to -- have of that's do that phage our the sure the make of

I think that -clinical more to the we've bacteria patients to have, is and going learned pre work. the likely tend through phage more our the both clinical work

make minimum definitely you've producing sputum the So take sure the that sample. threshold to regents enough have we of order got a bacteria, are in

some putting you parameters that's in, and to that have the definitely we're of So want there.

into -- think think we're one and been the getting for patients experiencing encouraged years. that emails struggling hand, infections with I to by study incoming on these from the and want enroll I

got system needs a is waves of for let's definitely disconnected few they there. after rebooted Omicron and other hope there's out So to the we be COVID lot to bay. a going But difficulties stay in and to patients and do I months, acknowledge think at the

threshold that included? you question for a again, be about to who Staph you derm them once get see have atopic need started is to a in but then those screening for there, And ask I'll aureus, there similar

you're Exactly, on. Yes. spot

of high on severe there reason the the there, you likely We think moderate to going are to based more to studies there, and effect. bacteria some the that KOLs are going have out I that one, and we're levels have been think of bacteria. is the that's have more out an

terms exactly rationale, B. cocktail right? those right? in the that's only that, taking minimum the make same want strains, And clinical the relevant. their timeline about situation that threshold, the A. we're and to And the relevant definitely enroll. a are also don't not patients our patients are We executing are worried of where the their There skin COVID, We threshold. That's is right? that So We're we patients not in is to in sure not phage the the strains here we're minimum swabs. Have issue. treating proceeding Those study and can be original

think are still. talked we I at logistical seeing of we issues about some the CRO the that

for Thanks right. the All Okay. caller.

You Thanks, bet. Keay.

Thank floor I'll we for to Instructions] the time, further appears It no you. questions. remarks. [Operator turn additional have this At management

fibrosis Though please us and a Have months. this have atopic future clinical to questions. our on any you, you you, -- you for again, all joining morning, look day, of XX dermatitis wonderful if reach us throughout next to the cystic out programs we thank with forward providing updates and

This lines time. your today's will participation, at now this for may Thank disconnect your you conclude conference. you